SCHEMBL3985677

SCHEMBL3985677

O=C(O)c1c(NS(=O)(=O)c2ccc(Cl)cc2)ccc2ccccc12

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 4/20 0.82
METAP1 P53582 1/20 0.82
HKDC1 Q2TB90 1/20 0.58
KEAP1 Q14145 1/20 0.56
NFE2L2 Q16236 1/20 0.56
CHEK1 O14757 1/20 0.52
CDK8 P49336 1/20 0.52
NEK2 P51955 1/20 0.52
LIMK1 P53667 1/20 0.52
HTR1A P08908 1/20 0.52
HTR2A P28223 1/20 0.52
HTR7 P34969 1/20 0.52
HTR6 P50406 1/20 0.52
RECQL P46063 1/20 0.51
CCR1 P32246 1/20 0.51
CCR2 P41597 1/20 0.51
KCNA5 P22460 1/20 0.51
HSP90AA1 P07900 2/20 0.50
HSP90AB1 P08238 2/20 0.50
ERBB2 P04626 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3986500 0.90 METAP2 (1.00) METAP2METAP1CHEK1CDK8NEK2
SCHEMBL3987782 0.87 METAP2 (0.82) METAP2METAP1KEAP1NFE2L2CHEK1
SCHEMBL3982656 0.87 METAP2 (1.00) METAP2METAP1KEAP1NFE2L2CHEK1
SCHEMBL3984291 0.87 METAP2 (0.82) METAP2METAP1HKDC1KEAP1NFE2L2
SCHEMBL27676228 0.85 METAP2 (0.78) METAP2METAP1CHEK1CDK8NEK2
SCHEMBL3987476 0.84 METAP2 (0.76) METAP2METAP1KEAP1NFE2L2CHEK1
SCHEMBL3984259 0.84 METAP2 (0.76) METAP2METAP1HKDC1KEAP1NFE2L2
SCHEMBL3980582 0.81 METAP2 (0.64) METAP2METAP1CCR2MEN1KMT2A
SCHEMBL3985999 0.80 METAP2 (0.74) METAP2METAP1KCNA5ALDH1A1MEN1
SCHEMBL3985138 0.79 METAP2 (0.62) METAP2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-04-08 US claimed
US-7491718-B2 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES (US) 2009-02-17 US disclosed
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity ABBVIE INC. 2004-08-26 US disclosed
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-08-12 US disclosed
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885METAP1 2/4885HKDC1 2768/4885
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885METAP1 2/4885HKDC1 2768/4885
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885METAP1 2/4885HKDC1 2768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.